Pretreatment with the specific AT 1 receptor antagonist losartan blocked the pressor responses induced by the subsequent infusion of both analogs indicating that they act via the AT 1 receptor subtype. These results suggest that 3 the brain AT 1 receptor may be designed to preferentially respond to AngIII, and AngIII's importance as a centrally active ligand has been underestimated.
and AT 2 subtypes (7, 11, 44, 47) . Both the AT 1 (23, 24, 33) and AT 2 receptor subtypes (26, 32) have been cloned and sequenced. In rodents the AT 1 receptor subtype appears in two forms, AT 1A and AT 1B , both are G-protein coupled (14, 23, 38) . The AT 1A subtype mediates the classic functions of the brain RAS, including cardiovascular control, body water balance, cyclicity of reproductive hormones, vasopressin and oxytocin release (for review see Refs. 2, 3, 17, 27, 28, 37, 43, 46) . Recently, the use of gene targeting has suggested that the AT 1B subtype is responsible for the majority of AngII-induced drinking in mice (8, 9) . The AT 2 receptor subtype also appears to be G-protein coupled (26, 32) , and is maximally activated by AngIII although it also binds AngII (for review see Ref. 49 ). This subtype mediates the processes of apoptosis, tissue regeneration and wound healing (12, 19, 45) . It is now generally agreed that conversion of brain AngII to AngIII is primarily accomplished by aminopeptidase A (APA: EC 
METHODS
The research conducted in this investigation conformed with the "guiding principles for research involving animals" as adopted by the American Journal 
Compounds
The structure, molecular weight, peptide content, and source of each compound utilized in these experiments are provided in Table 1 Peptide purity ranged from 98 to 100 percent while acetate represented the major contributor to the decreased purity by weight. These peptides were adjusted for purity such that the doses reflected actual peptide delivered in moles. EC33 and PC18 were synthesized in the laboratory of B P Roques according to previously described procedures (6, 18) , with purities determined to be 98 percent. Losartan was obtained as a gift from Dr. Ronald D. Smith, DuPont-Merck, Wilmington, DE. Table 1 about here 
RESULTS

Experiment 1: dose-response curves
There were no differences among the groups infused with AngII, AngIII, AngIII. There were no differences among these compounds with regard to maximum MAP collapsing across doses (F 3/28 =0.96, P>0.10). However, there was an expected dose effect (F 3/84 =2.77, P<0.05).
Post-hoc analyses indicated that each increment in dose produced significantly 14 greater pressor responses than the previous dose. There was no significant ligands X doses interaction. Figure 1 about here   --------------------------------------------- AngII as compared with the two other groups, that did not differ.
---------------------------------------Insert Figure 2 about here ---------------------------------------
As shown in Figure 2A There was an expected dose effect (F 3/63 =69.58, P<0.0001). Post-hoc analyses revealed that each increment in dose yielded a significantly greater MAP.
Finally, the groups X doses effect was also significant (F 6/63 =8.32, P<0.0001).
Post-hoc analyses established that members of the group pretreated with EC33 revealed MAP levels not different from aCSF pretreatment at each dose of D- respectively, P<0.001).
-------------------------------------------------------
Insert Figure 3 about here   ------------------------------------------------------- 
DISCUSSION
Some years ago our laboratory (50-52) and others (16) 55). Song and colleagues (39) came to the same conclusion concerning both blood pressure and dipsogenic responses using an antibody against APA.
These previous results are very important with regard to identifying the active ligand of the brain RAS, however several procedural shortcomings became apparent. The shortcomings included the following: 1) A major portion of this previous work with EC33 and PC18 was conducted utilizing anesthetized rats, thus increasing the risk of dampened pressor responding. The present investigation utilized alert rats. 2) Bolus icv injections were used rather than icv infusions, as presently employed, that provide a more stable pressor response.
3) Native AngII and AngIII were used as ligands. It has been previously reported that AngII and AngIII are rapidly metabolized in vivo (13, 22) . AngII. Although preliminary these findings support the notion that AngII must be converted to AngIII in order to bind at this receptor subtype.
Taken together these results confirm, and significantly extend, previous findings utilizing EC33 and PC18 (35, 36) . In agreement with this earlier work pretreatment with EC33 prevented any pressor response to the infusion of AngII (presently an AngII analog), while EC33 had no effect on AngIII-induced (presently an AngIII analog) pressor responding. Pretreatment with PC18
significantly potentiated the pressor effect and duration of AngIII (presently an AngIII analog). The present investigation extended previous work by testing whether pretreatment with PC18 also potentiated the pressor effect of an AngII analog, which it did not, although it did significantly extend the duration of the 
